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miR-223Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a common complication of CKD, and uremic
toxins have been shown to be instrumental in this process.We have previously shown that miR-223 is increased
in smooth muscle cells subjected to the uremic toxin inorganic phosphate (Pi). In the present study we investi-
gated the inﬂuence of this miRNA in osteoclastogenesis in order to elucidate its role in the course of CKD-MBD.
RT-qPCR demonstrated that high Pi concentration decreased miR-223 expression in differentiated RAW 264.7
cells. Up- and down-regulation of miR-223 was performed using speciﬁc pre-miR and anti-miR-223. Differenti-
ation of monocyte/macrophage precursors was assessed by using RAW 264.7 cells and peripheral blood mono-
nuclear cells (PBMC). TRAP activity and bone resorption were used to measure osteoclast activity. Pi induced a
marked decrease in osteoclastogenesis in RAW cells and miR-223 levels were concomitantly decreased. Anti-
miR-223 treatment inhibited osteoclastogenesis in the same way as Pi. In contrast, overexpression of miR-223
triggered differentiation, as reﬂected by TRAP activity. We showed that miR-223 affected the expression of its
target genes NFIA and RhoB, but also osteoclast marker genes and the Akt signalling pathway, which induces
osteoclastogenesis. These results were conﬁrmed by measuring bone resorption activity of human PBMC differ-
entiated into osteoclasts. We thus demonstrate a role of miR-223 in osteoclast differentiation, with rational
grounds to use deregulation of this miRNA to selectively increase osteoclast-like activity in calciﬁed vessels of
CKD-MBD. This approach could alleviate vascular calciﬁcation without altering bone structure.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Chronic kidney disease-mineral and bone disorder (CKD-MDB) is
characterized by mineral, bone, and cardiovascular abnormalities [1].
This syndrome is eventually responsible for clinical and histological
bone abnormalities that ﬁnally lead to cardiovascular disease. A bone-
vascular cross-talk takes place between calciﬁcations in the arterial
wall and bone disorders which are observed in renal osteodystrophyMDB, chronic kidney disease-
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etzinger).and related pathologies such as osteomalacia or adynamic bone disease
[2]. The presence of vascular calciﬁcations (VC) is correlated to in-
creased mortality rates in patients with CKD compared to the general
population [3]. It is therefore of interest to study the impact of uremic
toxins, especially inorganic phosphate (Pi) which is nowwell described
as a main VC inducer, on both bone tissue and vessels.
Until recently, little was known about the effect of Pi on mature oste-
oclasts and their precursors. Osteoclasts are multinucleated cells that re-
sorb bone tissue by removing its mineralized matrix and breaking up
the organic bone matrix [4]. They are characterized by high expression
of speciﬁcmarkers like tartrate-resistant acid phosphatase (TRAP), osteo-
protegerin (OPG), Akt phosphokinase, tumour necrosis factor-α (TNF-α)
and nuclear factor kappa B (NF-κB). Osteoclastogenesis requires the pres-
ence of receptor activator of nuclear factor κβ (RANK) and its ligand,
RANK-ligand (RANKL), as well as macrophage colony-stimulating factor
(M-CSF) [5]. RANKL in turn activatesNF-κB and its related signalling path-
way via RANK [6].
We previously found that increased Pi inhibits both osteoclast dif-
ferentiation and the bone resorption process [7]. Enhanced levels of Pi
were found to speciﬁcally inhibit osteoclastic differentiation by exerting
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mechanisms involvedwere inhibition of Akt and JUN activation induced
by RANKL, followed by a reduction of the DNA-binding ability of NF-kB
[7]. Pi inhibited both osteoclastic differentiation and bone resorption at
concentrations ranging from 3 mM to 4.5 mM [7]. That is why we
choose to focus in this work on 3mM Pi, which is the lowest concentra-
tion that reproducibly inhibits osteoclastogenesis, and a concentration
found in hemodialyzed CKD patients [1]. Another study showed that
mice treated with phosphate binders displayed increased osteoclast
activity and number, demonstrating a link between Pi content, osteo-
clasts and CKD-MBD [8]. Interestingly, the existence of multinuclear
osteoclast-like cells has beendemonstrated in vessels in somepatholog-
ical calciﬁcation processes [9]. However, these cells are elusive and
sparse, suggesting that a decreased number of cells, notably triggered
by Pi and/or other uremic toxins, predisposes to the development of
VC during the course of CKD [10].
The present study expanded on these works by looking at the role of
microRNAs (miRNAs),which represent a recent breakthrough concerning
gene expression regulation [11]. The roles of many miRNA during osteo-
clastogenesis have been recently summarized, as they play important
roles in osteoblast and osteoclast biology and consequently modulate
bonepathophysiology [12].miRNAs comprise a novel class of endogenous
small non-coding RNAs that negatively regulate gene expression via
degradation or translational inhibition of their target mRNAs [13]. More
importantly, one miRNA is able to regulate the expression of multiple
genes because it can bind to its mRNA targets as either an imperfect or
perfect complement. miR-223, which was ﬁrst described as a modulator
of haematopoietic lineage differentiation, is also deregulated in several
types of cancers and has an emerging role in inﬂammatory andmetabolic
disorders, particularly muscle diseases, type II diabetes, atherosclerosis
and VC (e.g. Kim et al. [14], Guo et al. [15], recently reviewed in [16]).
Interestingly, mir-223 is one of themainmiRNAs involved in osteoclasto-
genesis. Indeed, Kagiya et al. found miR-223 to be downregulated during
osteoclastogenesis [17]. miR-223 upregulation is implicated in stimulat-
ing differentiation and function of osteoclasts via negative regulation of
NFI-A levels [18]. In the same study, inhibition ofmiRNA-223 deregulated
TRAP-positive osteoclast formation in RAW264.7 cells [18]. In the context
of VC, we have previously shown that miR-223 is increased in smooth
muscle cells subjected to the uremic toxin Pi [19] and in the aorta of
mice with CKD [20], and we therefore decided to study the role of this
miRNA in osteoclastogenesis, to elucidate the interplay between bone
and vessels during the course of CKD-MBD.
The role played by miRNAs, including miR-223, in modulating the ef-
fect of Pi on osteoclastogenesis has not been evaluated. In this study, we
therefore decided to assess the effects of an uremic concentration of Pi
(as deﬁnedby theEUToxwork group [21]), in parallelwithmiR-223over-
expression or antagonizing strategies, on osteoclast differentiation and
bone-resorbing activity. We studied osteoclast differentiation in two
cellularmodels ofmonocyte–macrophage progenitors, human peripheral
blood mononuclear cells (PBMC) and murine RAW 264.7 cells and
showed that Pi induces a marked decrease of osteoclastogenesis with a
concomitant decrease of miR-223 levels. AntagomiR treatment directed
againstmiR-223 decreased osteoclastogenesis, while overexpression trig-
gered this process in the RAW precursor cell line. We showed that miR-
223 affects expression levels of its speciﬁc targets (RhoB/NFIA) as well
as osteoclastogenesis targets (OPG/TNF-α/NF-κB), but also TRAP activity
and the Akt-phosphokinase related signalling pathway, a well-known
actor of osteoclastogenesis. Finally, we conﬁrmed thatmiR-223 affects os-
teoclast function in human PBMC differentiated into osteoclasts.
2. Material and methods
2.1. Chemicals
α-Modiﬁed Eagle's Medium (α-MEM), Dulbecco's Modiﬁed Eagle's
Medium (DMEM), Roswell Park Memorial Institute (RPMI) mediumand Histopaque were obtained from Sigma. All media were supple-
mented with 1% glutamine (Sigma) and 1% penicillin-streptomycin
(Sigma) prior to use. Heat-inactivated foetal calf serum (FCS) was
obtained from Dominique Dutscher, and human recombinant RANKL,
murine recombinant RANKL, and human recombinantM-CSFwere pur-
chased from R&D Systems. Antibodies were purchased from Santa Cruz
Biotechnology, INC. All other reagents were obtained from Sigma.2.2. PBMC and RAW 264.7 cell culture and differentiation
Culture of RAW 264.7 murine monocyte/macrophage cell (ATCC)
has beenpreviously described byMozar et al. [7]. Brieﬂy, Cellswere rou-
tinely cultured in DMEM containing 10% FCS [7]. All media were supple-
mented with 1% glutamine/1% penicillin-streptomycin prior to use. For
differentiation experiments, RAW 264.7 cells were gently scraped and
seeded in 96-well plates (Corning) at a density of 5 × 103 cells per
well in α-MEM differentiation medium supplemented with 10% FCS.
After 2 h, the media was renewed and treated or not with 50 ng/ml of
recombinant murine RANKL. Media were replaced on the third day
and cells were cultured for a total of 5 days. Throughout themanuscript,
cells cultured without RANKL are designated as the negative control
(C−), and cells treated with recombinant murine RANKL, and thus
differentiated, are the positive control (C+). Differentiated cells treated
with the scrambled RNA control are referred to as C+S. The absence of
differentiation when RANKL was omitted was conﬁrmed visually in all
experiments. Cells were cultured for a total of 5 days. 3 mM Pi concen-
tration was reached by taking into account the basal Pi concentration
(approx. 1–1.1 mM when one considers the relative % of SVF) of the
culture medium.
Peripheral blood mononuclear cells (PBMC) culture was performed
as described by Mozar et al. [7]. Whole blood was provided by the
Centre de Transfusion Sanguine of Amiens and human PBMC were iso-
lated using Histopaque (Sigma, density gradient centrifugation =
1.077). Isolated cells were plated in 48-well plates at a density of
5 × 105 cells per well to a ﬁnal volume of 300 ml of RPMI containing
10% FCS. Cells were cultured for 14 days. All media were supplemented
with 1% glutamine/1% penicillin-streptomycin prior to use, and all
media and added factors were replaced twice a week.2.3. Transfection of pre-miR-223 and anti-miR-223
The siPORT NeoFX transfection agent (Applied Biosystems) was
used for miRNA knock-down and overexpression, according to the
manufacturer's instructions and as previously described [19]. RAW
264.7 cells were seeded in 24-well or 96-well culture plates (Corning)
with 103 and 5 × 103 cells respectively. They were concomitantly treated
with RANKL, with 3 mM Pi, as previously indicated, and/or transfected
with irrelevant scrambled RNA, anti-miR-223 or pre-miR-223 (Applied
Biosystems). Cells were then collected and processed for further analysis
after a total of 5 days in culture.2.4. Protein preparation and Western blotting
For total protein preparation, cells were harvested after 5 days in
culture by scraping and centrifuged at 600 ×g for 10 min at 4 °C. As
previously described [7], cell pellets were resuspended in lysis buffer
supplemented with protease inhibitor mixture (Roche Diagnostics).
Homogenate was centrifuged 15 min at 14,000 g at 4 °C to remove cell
debris and nuclei. Each protein sample (50 μg) was resolved by sodium
dodecyl sulphate–polyacrylamide gel electrophoresis, transferred onto
a polyvinylidenediﬂuoride membrane, and incubated with antibodies
against RhoB, NFIA, Akt (Santa Cruz, 1:500), or β-actin (1:10,000;
Sigma-Aldrich). The signals were detected by incubation with labelled
secondary antibodies using the ECL Detection System (GE Healthcare).
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RNAs were isolated with the mirVana™ Isolation Kit (Applied
Biosystems) according to the manufacturer's instructions. Applied
Biosystems Taqman assays were used for RT-qPCR to determine
miRNA level expression, as previously described [19]. For phenotypic
marker genes, 1 μg of DNAse-I-digested RNA was reverse-transcribed
using a High-Capacity cDNA Synthesis Kit (Applied Biosystems). Quan-
titative real-time PCR were then run on a StepOnePlus system (Applied
Biosystems) using the primers described in Table 1. The U6 small nucle-
ar RNA andGAPDHmRNAwere used as endogenous controls formiRNA
and mRNAs, respectively.
2.6. TRAP staining
PBMC and RAW264.7 cells were ﬁxed and stained for TRAP, a mark-
er enzyme of osteoclasts, using a commercially available kit (leukocyte
acid phosphatase staining Kit 387 A, Sigma), as previously described
[7]. Brieﬂy, cells were washed with PBS and ﬁxed in 3.7% formaldehyde
for 10min. According to themanufacturer's protocol, cells were then in-
cubated for 10–15min (37 °C) in the staining solution and rinsed twice
with PBS. Multinucleated (N3 nuclei) TRAP-positive cells were counted
as osteoclasts on microscopic examination.
2.7. Determination of TRAP activity
RAW 264.7 cells were lysed and incubated for 30 min in a reaction
buffer containing paranitrophenyl phosphate (pNPP) [7]. The reaction
was stopped with 0.3 N NaOH. ODs were then measured at 405 nm
against a reference wavelength of 650 nm using a microplate reader
(Biorad). The ODs were compared to a standard curve calibrated with
paranitrophenol (pNP), and protein concentrations were quantiﬁed
using the Biorad protein assay. Results were expressed as % of selected
control (C+S).
2.8. Bone resorption activity: pit area measurement
PBMCwere cultured as described above, and the resorption lacunae
(pits) counting and percentage of resorbed bone areawere estimated as
previously described [7]. Brieﬂy, cells were seeded on bovine bone slices
(6mm in diameter) pre-positioned in thewells. After 2 h, non-adherent
cells were gently washed out from wells and 300 ml of fresh α-MEM
supplemented with 10% FCS, human RANKL (25 ng/ml), and human
M-CSF (30 ng/ml) were added, with or without Pi. Concomitantly,
cells were transfected with scramble, pre-miR-223 or anti-miR-223.
All treatments were given at the start of the experiment, and media
and added factors were replaced twice a week. Cells were cultured for
14 days. At the end of the experiment, the number of osteoclasts
(TRAP staining) and the resorbing activitywere determined. For resorp-
tion analyses, TRAP positive osteoclasts were removed from the bone
slices. The resorption lacunae (pits) were visualized by staining theTable 1
Primers used in this study (fw, forward; rv, reverse).
Gene Primers Sequence
GAPDH GAPDH fw AACTTTGGCATTGTGGAAGGGCTC
GAPDH rv TGGAAGAGTGGGAGTTGCTGTTGA
NF-κB NFKB fw CTGATGAAAGGAGGGAGCACG
NFKB rv AGCAGGGAAGGGTTGG
NFIA NFIA fw CAGCATCACCGACCTGTCAT
NFIA rv GCCCAGGCTGCTGGATAA
Osteoprotegerin OPG fw TCCCTTGCCCTGACCACTCTT
OPG rv CAGGTAACGCCCTTCCTCACA
RhoB RHB_fw GAGAACATCCCCGAGAAG-G
RHB_rv CTTCCTTGGTCTTGGCAGAG
TNF-α TNF fw ATGAGCACAGAAAGCATGATC
TNF rv TACAGGCTTGTCACTCGAATTbone slices with haematoxylin red and toluidine blue solution contain-
ing 1% sodium borate, and imaged by light microscopy. We counted as
resorption pits an eroded surface of approximately the size of amultinu-
cleated cell (with a number of nuclei ≥3), knowing that resorption pits
could of course be larger. Total area of the investigated ﬁeld, resorbed pit
area, and the number of pits per ﬁeld were determined manually with
help of the software Bonoscan, developed and provided by Microvision
which allowedus to spot the pits and the resorbed surface and the surface
of thewhole ﬁeld. Results could be sorted out ﬁeld by ﬁeld or bymeaning
all the ﬁelds. The resorption rate was calculated by the software by divid-
ing the resorbed surface by the whole surface.
2.9. Statistical analysis
Data are expressed as mean ± standard deviation. The statistical
signiﬁcance of differences between the experimental and control
groups was evaluated by independent Student's t test when we com-
pared control to high Pi treatment, or by the ANOVA test when three
or more means were compared.
3. Results
3.1. Pi induces a marked decrease of osteoclastogenesis in RAW cells which
is related to concomitant decrease of miR-223 levels
Our group previously reported that 3 mM Pi, a concentration found
in CKD patients, decreases osteoclastic differentiation [7,22]. This ﬁnd-
ing was conﬁrmed in the present study (Fig. 1A). In our model, we
then screened a non-exhaustive panel of miRNAs that have been
described as being deregulated during bone metabolism at the time of
induction of osteoclastogenesis. Quantitative real-time PCR evidenced
intense downregulation of most of the osteogenesis-associated miRNAs
studied when RAW 264.7 cells were treated with 3mMPi (Fig. 1B). The
downregulated miRNA included miR-21 [23] (71% of control), miR-29b
[24] (66%of control),miR-135a [25] (53%of control),miR-155 [18] (52%
of control) andmiR-223 [26] (49% of control). In contrast, miR-92a [27],
miR-133a [25] and miR-148a [28], were upregulated (118%, 191% and
551% of control, respectively). On the other hand, treatment with high
Pi concentrations did not signiﬁcantly affect miR-126, an irrelevant
miRNA which is mostly described as an endothelial-speciﬁc miRNA
andwhich, to the best of our knowledge, is not implicated in osteoclasto-
genesis [29], andmore surprisingly Pi did not changemiR-34a expression
either, although miR-34a has been recently described as a key osteoclast
suppressor [30]. As further controlwe also veriﬁed that U6was not signif-
icantly modiﬁed by Pi treatment (data not shown). As miR-223 was one
of the most deregulated miRNAs in our experiments, and because it has
already been widely implicated during osteoclastogenesis [17,26,31,32],
we decided to focus on the effect of this miRNA and to modulate its ex-
pression in order tomore precisely deﬁne its role in Pi-induced downreg-
ulation of osteoclastogenesis. Obviously, the deregulation of the other
miRNAs could be a matter of further investigations.
3.2. Decreased miR-223 inhibits osteoclastogenesis, while miR-223
overexpression enhances differentiation
RAW 264.7 cells were transfected with pre-miR-223 (to induce
overexpression) or anti-miR-223 (to knock-down expression) and
treated with either 3 mM Pi or 50 ng/ml RANKL, or with RANKL plus
Pi for 5 days, and then processed for TRAP staining. A scrambled, irrele-
vant RNA was used as control (C+S) throughout the experiment. As
expected, an increase of approximately 30-fold in differentiated cells
was observed when pre-miR-223 was used and a signiﬁcant (75% of
control) decrease was detected when anti-miR-223 was used, relative
to control experiments with scrambled RNA (Fig. 2A). We also checked
that our reference geneU6was not signiﬁcantlymodiﬁed by the various
treatments (data not shown). In all experimental conditions, miR-223
Fig. 1. Pi induces amarked decrease in osteoclastogenesis in RAWcells with a concomitant decrease inmiR-223 levels. A. Pi inhibits RANKL-induced differentiation of RAW264.7 cells into
TRAP-positivemultinucleated cells. RAW264.7 cells were cultured for 5 days in the presence of RANKL (50 ng/ml) and 3mMPi.Multinucleated osteoclast differentiation from RAW264.7
cells was assessed in each well. B. miRNA TaqMan microRNA assays (Applied Biosystem) on total RNA after 5 days in culture. Quantitative polymerase chain reaction (PCR) analysis of
osteoclastogenesis-relatedmiRNAs in RAW264.7 cells cultured inDMEM containing 10% FBS for 5 days in the presence of soluble RANKL (50 ng/ml) and treatedwith 3mMof Pi compared
to control cells treatedwith the basal concentration of Pi (n= 6). U6 small nuclear RNAwas used as an internal reference gene. Results were normalized to C+whose value was set to 1.
* P b 0.01, ** P b 0.05, *** P b 0.001; 3 mM Pi vs. control, differentiated cells treated with recombinant murine RANKL: C+.
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to cell cultures incubated with basal Pi concentration (18% decrease
in scrambled RNA, 20% decrease in cells with miR-223 overexpression,
and 40% decrease in cells with miR-223 under-expression). We then
studied the effect of miR-223 deregulation on RAW 264.7 cells osteo-
clastogenesis by counting TRAP-positive osteoclasts andmeasuring cor-
responding TRAP activity. Multinucleated (N3 nuclei) TRAP-positive
cells were counted as osteoclasts on microscopic examination and pos-
itive cells were pictured (Fig. 2B). Anti-miR-223 and 3mMPi treatment
both signiﬁcantly and intensely inhibited RANKL-induced differentia-
tion of RAW 264.7 cells into TRAP-positive multinucleated cells (60%
decrease for Pi and 48% decrease for anti-miR-223). Interestingly, both
molecules induced comparable changes, suggesting a link between the
two treatments (Fig. 2B). Furthermore, pre-miR-223 induced a mild
but signiﬁcant, 18%, increase in the number of osteoclasts. When com-
bining Pi and pre-miR-223, differentiation levels reached the ones of
the control. A combination of both Pi and anti-miR-223 decreased
differentiation even further than treatments given separately (20% de-
crease when compared to Pi alone, Fig. 2B). Consequently TRAP activitywas assessed, as TRAP is widely considered to be a marker of osteoclast
biochemical activity and released in large quantities by osteoclasts [33].
As expected from the previous results, Pi decreased TRAP activity by ap-
proximately one third when incubated with cells treated with the
scrambled control RNA. Anti-miR-223 treatment induced a signiﬁcant
and marked decrease in TRAP activity, by almost one half, conﬁrming
data obtained for osteoclast number, and cumulative treatment with
both Pi and anti-miR-223 did not trigger any further signiﬁcant de-
crease. On the other hand, a signiﬁcant and marked 1.6-fold increase
of TRAP activity was observedwhenmiR-223 expressionwas enhanced
via pre-miR treatment. Pi inhibited this increase, levelling miR-223
levels to the ones induced by Pi alone, suggesting that Pi has a strong
and direct interaction with the pathway targeted by miR-223.
To test the hypothesis that high Pi inhibits osteoclastogenesis by
modulating miR-223 expression in osteoclastogenesis, we ﬁrst treated
RAW cells with anti-miR-223 for 48 h to knockdown the expression of
miR-223, then treated cells for 48 h with 3mMPi, or 1.1mM as control.
In these experimental conditions, anti-miR-223 used alone still
decreased the number of TRAP positive cells by half but high Pi did
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(Supplemental Fig. 1). As control, we also veriﬁed that in the same
experimental conditions, high Pi used alone still decreased the number
of TRAP positive cells by half. This result suggests that decreasing miR-
223 expression is an important mechanism involved in the inhibition
of osteoclastogenesis by high Pi. We cannot however exclude that
other pathways are involved.3.3. Elevated Pi andmiR-223modulate the expression of reported targets of
miR-223
In a next step, we investigated, in our model, the effect of miR-223
regulation on the reported target RhoB [34]. RhoB, a member of the
Rho guanosine triphosphatase family of proteins, has been shown to
modulate cell proliferation andmediate adaptational changes to hypox-
ia [35]. When a miRNA is knocked down, its speciﬁc targets are in-
creased [11]. As expected, miR-223 downregulation by anti-miR-223
treatment signiﬁcantly increased the amount of RhoB mRNA (approxi-
mately 2-fold, Fig. 3A) with a concomitant increase of RhoB protein
(approximately 2.5-fold, Fig. 3B). Three mM Pi treatment induced very
similar dramatic changes in RhoB gene expression (3.2-fold increase
of RhoB mRNA, and 1.5-fold increase of RhoB protein). In addition, Pi
did not further affect RhoB levels in cells already treated with anti-
miR-223, conﬁrming that high Pi and anti-miR-223 do not have a syner-
gistic or cumulative effect on the inhibition of osteoclastogenesis. Pre-
miR-223 expectedly decreased the amount of RhoB mRNA (by approx-
imately one third although signiﬁcance could not be reached; Fig. 3A
and B) but did not signiﬁcantly change protein expression. mRNA de-
crease was prevented by incubation with 3 mM Pi.
Sugatani et al. have shown that NFIA, a negative regulator of M-CSF,
is an essential target of miR-223 [26]. Since NFIA is a well-documented
target ofmiR-223, we decided to study its expression in our experimen-
tal setup. As expected, in view of the results obtained with RhoB, the
amount of NFIA mRNA increased concomitantly with miR-223 down-
regulation (approximately 6.7-fold, Fig. 3A) with a concomitant in-
crease of NFIA protein (approximately 7-fold, Fig. 3C). Similarly, NFIA
mRNA and protein expression increased around 2-fold and 4-fold, re-
spectively, when treatedwith high Pi. High Pi did not induce any further
signiﬁcant effect on NFIA protein levels in RAW 264.7 cells pre-treated
with anti-miR-223 (approximately 6-fold for mRNA and 7-fold for
protein). Pre-miR-223 induced a mild, not signiﬁcant decrease of the
amount of NFIA mRNA (15%), and a concomitant almost signiﬁcant de-
crease of NFIA protein (P b 0.061). This decrease in NFIAmRNA and pro-
tein was inhibited by incubation with 3 mM Pi (Fig. 3A and C). For all
experiments, we checked that GAPDH was not signiﬁcantly modiﬁed
by the various treatments (data not shown).
3.4. Elevated Pi and miR-223 modulate the expression of osteoclast marker
genes and the Akt signalling pathway
To determine the intracellular mechanism of action of phosphate,
we investigated the effect of miR-223 modulation and 3 mM Pi on
mRNA levels of osteoclast marker genes NF-κB [36], TNF-α [37] and
osteoprotegerin (OPG). OPG, amember of the TNF-receptor superfamily
which is a decoy receptor of RANKL, is known to reduce the differentia-
tion of osteoclast precursors [38]. Interestingly, high Pi concentration
treatment induced a marked 11-fold increase in OPG levels (Fig. 4A).Fig. 2. Elevated Pi affects miR-223 expression in cells transfected with pre-miR-223 and
anti-miR-223. RAW 264.7 cells (5 × 103/well) were transfected with miR-223 precursor
and inhibitor and treated with 3 mM Pi or 50 ng/ml RANKL alone, or with RANKL plus Pi
for 5 days, and then stained for TRAP expression, TRAP-positive multinucleated osteoclast
differentiation from RAW264.7 cells was assessed in each well. A. After RNA extraction,
RT-qPCR was performed using miR-223. miR-223 expression was affected when cells
were treated with Pi, while the expression of mature miR-223 was intensely upregulated
by transfection of pre-miR-223 and decreased in the presence of anti-miR-223 (n = 4).
B. TRAP-positive cells were photographed (magniﬁcation ×100). Anti-miR-223 inhibited
RANKL-induced differentiation of RAW 264.7 cells into TRAP-positive multinucleated
cells. Multinucleated osteoclast differentiation from RAW 264.7 cells was assessed in
each well. Multinucleated (N3 nuclei) TRAP-positive cells were counted as osteoclasts
onmicroscopic examination (n=4). C. Quantiﬁcation of multinucleated osteoclast differ-
entiation from RAW264.7 cells using TRAP activity was performed under the same condi-
tions. Differentiated cells treated with recombinantmurine RANKL and control scrambled
RNA: C+S. Results were normalized to C+S whose value was set to 1. Values represent
means ± Standard Deviation. Data are representative of three independent experiments;
*P b 0.01, **P b 0.05, ***P b 0.001, treatment vs. scramble control (C+S). #P b 0.01,
## P b 0.05, 3 mM Pi vs. basal Pi.
Fig. 3. Elevated Pi andmiR-223modulate the expression of osteoclastmarker genes and reported targets of miR-223. Cells were cultured for 5 days in DMEM supplementedwith 10% FBS,
in the presence or absence of 3mMPi. A. After RNA extraction, RT-qPCRwas performed tomeasure NFIA and RhoB using GAPDHas an internal reference (n=3). Black bar=RhoBmRNA
expression,white bar=NFIA RNA expression B. Total proteinswere analysed byWestern blot using antibodies speciﬁc for RhoB andNFIA. Representative immunoblot of cells transfected
with miR-223 precursor and inhibitor and/or treated with 3 mM Pi or 50 ng/ml RANKL alone, or with RANKL plus Pi for 5 days. Differentiated cells treated with recombinant murine
RANKL: C+S. Results were normalized to C+S whose value was set to 1. (n = 4). *P b 0.01, **P b 0.05, ***P b 0.001, treatment vs. scramble control (C+S). #P b 0.01, ##P b 0.05, 3 mM
Pi vs. basal Pi. Values represent means ± standard deviation.
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cordingly induced a signiﬁcant decrease, which was alleviated by Pi
treatment (Fig. 4A). When incubated with both Pi and anti-miR-223,OPG levels were enhanced even further, by 16-fold. NF-κB mRNA
levels were regulated in a manner opposite to OPG. Pi treatment sig-
niﬁcantly decreased NF-κB levels, by approximately half (Fig. 4B).
Fig. 4. Elevated Pi andmiR-223modulate the expression of osteoclastmarker genes and of the Akt signalling pathway. Cells were cultured for 5 days inDMEM supplementedwith 10% FBS,
in the presence or absence of 3 mM Pi. Total RNA was extracted, reverse-transcribed and expression of NFκ-B (A), TNF-α (B) and OPG (C) was analysed, using GAPDH as an internal ref-
erence (n= 3). D. Total proteins were extracted and analysed byWestern blot using antibodies speciﬁc for Akt and phosphorylated Akt. Representative immunoblot of cells transfected
withmiR-223 precursor and inhibitor and/or treatedwith 3mMPi or 50 ng/ml RANKL alone, or with RANKLplus Pi for 5 days. β-actinwas used as endogenous control. Differentiated cells
treatedwith recombinantmurineRANKL: C+S. Resultswere normalized to C+Swhose valuewas set to 1. (n=3) * P b 0.01, ** P b 0.05, *** P b 0.001, treatment vs. scramble control (C+S).
#P b 0.01, ##P b 0.05, 3 mM Pi vs. basal Pi. Values represent means ± standard deviation.
2208 E. M'Baya-Moutoula et al. / Biochimica et Biophysica Acta 1852 (2015) 2202–2212Again, anti-miR-223 had exactly the same effect as 3 mM Pi, where-
as pre-miR-223 increased levels by 1.6 fold, an increase that was
reversed by addition of Pi. Combined high Pi and anti-miR-223
treatment almost abolished NF-κB mRNA expression as it was de-
creased by 5-fold (Fig. 4B). We next looked at the expression of
TNF-α, as this cytokine was described as a co-actor in osteoclasto-
genesis [37]. We found that TNF-α levels were affected in the
same manner as NF-κB levels, as Pi and anti-miR-223 signiﬁcantly
decreased TNF-α levels (Fig. 4C).In addition, we investigated the Akt activation state involved in the
RANKL signalling pathway using the RAW264.7 cell line [7]. Akt activa-
tion was determined by Western blot using antibodies speciﬁcally di-
rected against the phosphorylated form of the enzyme, compared to
data obtained with antibodies directed against total Akt. We investigat-
ed the effect of miR-223 under our experimental conditions (Fig. 4D).
In our hands, neither Pi, pre-miR-223 or a combination of the two
treatments signiﬁcantly impacted on Akt phosphorylation, although Pi
treatment reached near signiﬁcance (P b 0.054). However, anti-miR-
2209E. M'Baya-Moutoula et al. / Biochimica et Biophysica Acta 1852 (2015) 2202–2212223 induced amarked twofold increase in Akt phosphorylation thatwas
not further affected by incubation with 3 mM Pi (Fig. 4D).
3.5. Inhibition of RANKL-induced osteoclastic bone resorption of PBMC-
differentiated osteoclasts by Pi and Anti-miR-223
To study the effects of Pi andmiR-223 on the ability of osteoclasts to
resorb bone, PBMC were cultured for 14 days on bovine bone slices in
the presence of RANKL (25 ng/ml), M-CSF (30 ng/ml), andwere treated
with 3 mM Pi and transfected with pre-miR-223 or anti-miR-223. After
a 2-week culture period under appropriate conditions, PBMC seeded
onto bovine bone slices showed evidence of differentiation into multi-
nucleated TRAP-positive cells (Fig. 5A) and bone resorption appeared
as characteristic pits on the surface of the slices. The effects of the
various treatments (Pi, pre-miR-223 or anti-miR-223) on osteoclastic
bone resorption were assessed by measuring two parameters: number
of bone resorption pits and resorption rate. The number of bone resorp-
tion pits was decreased by the same order of magnitude (30 to 55%
decrease, Fig. 5B) whether the cells were treated by 3 mM Pi, anti-
miR-223 or a combination of the two. Surprisingly, pre-miR-223 treat-
ment did not affect this parameter when administered alone, although a
trend towards protection against Pi treatment was observed (30% de-
crease vs 55% for Pi alone). The difference was however not statisticallyFig. 5. Inhibition of RANKL-induced osteoclastic bone resorption of PBMC differentiated osteoclasts
ence of RANKL (25 ng/ml), M-CSF (30 ng/ml), treated with 3 mM Pi and transfected with Pre-m
B. Effects of Pi and/or pre-miR-223 or anti-miR-223 on osteoclastic bone resorption, as asses
osteoclastic bone resorption, expressed in resorption rate (resorbed area/total area). Results
** P b 0.05, *** P b 0.001, treatment vs. scramble control (C+S). #P b 0.01, ##P b 0.05, 3 mM Pi vssigniﬁcant. Similar results were obtained for the percentage of resorbed
bone area (Fig. 5C). More precisely, this parameter decreased (ranging
from 45 to 65%) in cells treated by 3 mM Pi, anti-miR-223 or a combina-
tion of the two, with no cumulative effect. Again, pre-miR-223 treatment
induced a non-signiﬁcant trend towards an increase regarding this pa-
rameter. However, Pi treatment totally inhibited this trend and the per-
centage of resorbed bone area was similar to that observed when using
Pi alone (45% decrease vs 68% decrease for Pi alone).
4. Discussion
Osteoclastogenesis originates from mononuclear precursors and is
instrumental in vivo to regulate the bone resorption process [39]. It is
modulated, at least in part, by bone resorption products, such as calcium
and phosphate [7,40]. CKD patients with a glomerular ﬁltration rate less
than 15 to 30ml/min commonly display hyperphosphatemia [2]. Many
recent studies have shown that elevated serumPi is one of the causative
agents of and a risk factor for CKD-MBD, and is also associated with
cardiovascular mortality [3,2]. In CKD-MBD, vascular disorders, such as
VC, are accompanied by bone disorders, including pathologies observed
in renal osteodystrophy [2].We therefore examined the effect of high Pi
concentration on the ability of mononuclear precursors to differentiate
into osteoclasts. Conﬁrming previous work [7,40], we showed that Piby Pi and Anti-miR-223. PBMCswere cultured for 14 days on bovine bone slices in the pres-
iR-223 or Anti-miR-223. A. TRAP-positive cells were photographed (magniﬁcation ×100).
sed by resorption pits counting. C. Effects of Pi and/or pre-miR-223 or anti-miR-223 on
are expressed as percent of C+S, whose value was set to 1. (n = 12 slides). * P b 0.01,
. basal Pi. Values represent means ± standard deviation.
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known monocyte–macrophage progenitor models, PBMC and RAW
264.7 cells, and reported for the ﬁrst time a role for miRNAs in Pi-
induced modulation of osteoclastogenesis. Dicer and DGCR8 have both
been previously shown to be essential proteins for miRNA maturation.
In addition, knock-out of these proteins strongly suggested thatmiRNAs
are essential for osteoclastic bone resorption [41,42]. The roles of many
miRNA during osteoclastogenesis have been recently summarized, as
they have important roles in osteoblast and osteoclast biology and con-
sequently modulate bone pathophysiology [12]. Epigenetic control by
histone deacetylases (HDAC) are also part of the regulation of osteoclas-
togenesis by miRNAs, as for example HDAC-5 and -9 are respectively
targeted by miR-2861 [43] and miR-188 [44]. Recently, overexpression
of miR-148a has been shown to promote osteoclastogenesis in PBMC,
whereas inhibition ofmiR-148a attenuated this process [28]. In our con-
ditions, Pi enhanced stronglymiR-148a expressionwhile decreasing os-
teoclastogenesis. This increase inmiR-148a triggered by Pi could thus be
a counteracting response of the osteoclast cell to counteract the inhibi-
tory effect of Pi, but additional workwill be of course needed in an inde-
pendent work to explore this result. On the other hand, miR-34a
expressionwas not affected by Pi, although thismiRNA has been recent-
ly described as a key osteoclast suppressor [30]. One of the ﬁrst demon-
strations of role of miRNA in osteoclastogenesis was provided by
Sugatani and Hruska, who showed that reducing the total number of
miRNAs decreased osteoclast number and increased trabecular bone
mass [18]. The same group subsequently showed that miR-223 is a key
factor in osteoclastogenesis [26]. Shibuya et al. also found that miR-223
expression is affected during osteoclastogenesis and more precisely up-
regulated in rheumatoid arthritis synovium [32]. This is interesting in
the light of our ﬁnding that miR-223 was the miRNA most commonly
deregulatedbyPi among severalmiRNAs known tobederegulatedduring
osteoclastogenesis and/or osteoblastogenesis. We therefore conﬁrm pre-
vious results and expand on them by showing that increasing Pi and de-
creasing miR-223 expression both decrease osteoclastogenesis. Thus, we
decided to speciﬁcally focus on the inﬂuence of this miRNA on the role
of Pi in osteoclastogenesis although additional studies on the other mod-
ulated miRNA should be performed in a later time.
miR-223 upregulation is able to at least partly increase osteoclasto-
genesis, as evidenced by osteoclast number and TRAP activity in RAW
264.7 cells. Sugatani et al. [18] showed that NFIA, a negative regulator
of M-CSF, is an essential target of miR-223 and is able to facilitate oste-
oclast differentiation. We have recently shown that NFIA is targeted by
miR-223 in calcifying vascular smooth muscle cells [19]. Here, we con-
ﬁrm in another cellular model (RAW 264.7 cells) that NFIA is targeted
by miR-223 and show that Pi is also able to modulate the expression
of this DNA-bindingprotein that has been implicated in gene expression
and development [45]. Similar results were obtained when examining
the expression of another target ofmiR-223, RhoB, a transcription factor
involved in cell proliferation.
To further determine the intracellular mechanism of action of phos-
phate, we investigated the effect of miR-223 modulation and Pi regula-
tion onmRNA levels of threemajor players in osteoclastogenesis, NF-κB
[36], TNF-α [37] and OPG (a member of the TNF-receptor superfamily)
[38]. High Pi concentration and anti-miR-223 independently induced a
strong increase in OPG levels, whereas pre-miR-223 induced a signiﬁ-
cant decrease, which was alleviated by Pi treatment. Conversely, the
same treatments decreased NF-κB and TNF-α expression. TNF-α is a
potent bone-resorbing factor responsible for stimulating osteoclastic
bone resorption in vitro and in vivo [46]. It mediates RANKL stimulation
of osteoclast differentiation by activating NF-kB through intracellular
mechanisms overlapping those of RANKL [47]. We expectedly found
that TNF-α and NF-κB were regulated concomitantly. Since miR-223
knock-down and high Pi decrease TNF-α and NF-kB, they are expected
to decrease the osteoclastogenic process, and that is indeed what we
found in our PBMC model of bone resorption as high Pi concentration,
anti-miR-223 or a combination of the two decreased the number ofbone resorption pit and the resorption rate. OPG is able to bind to
RANKL and therefore competes for binding with RANK, thus blocking
the inducing effect of RANKL on the osteoclast differentiation [48]. The
increase in OPG that we observed in RAW 264.7 could in fact inﬂuence
negatively osteoclastogenesis by reducing the differentiation of osteo-
clast precursors [38]. It is thus consistent with our ﬁndings of dimin-
ished resorption rates and number of bone resorption pits in PBMC in
presence of Pi or anti-miR-223. However, pre-miR-223 had no signiﬁ-
cant effect although a trend towards protection against Pi treatment
was observed. This suggests that, in contrast to TRAP activity, the most
prominent features of osteoclast terminal differentiation, such as bone
resorption, are not affected by an increase of this miRNA.
Finally, we have previously shown that Akt is affected by Pi treat-
ment [7]. Akt activation by phosphorylation has been associated with
cell proliferation and tumour invasiveness [49], aswell as osteoclast sur-
vival [50]. Accordingly, by promoting Akt phosphorylation, decreased
miR-223 might facilitate osteoclast precursor cell proliferation before
fusion, that ﬁnally results in a higher number of osteoclast, as well as
osteoclast survival, in conjunctionwith its roles on NFIA and RhoB. Con-
versely, as expected, a decrease in osteoclast differentiation was ob-
served in the presence of anti-miR-223.
Our results are interesting in the context of the CKD-MBD process, in
which trans-differentiation of VSMC into vascular calcifying cells and
osteoclastogenesis are both affected by the same factors, including the
uremic toxin Pi, promoting both VC and renal osteodystrophy, respec-
tively. We have previously postulated that a decrease in the capacity
of monocytes/macrophages to differentiate into “osteoclast-like cells”,
in addition to mineralization by osteoblast-like cells in the arterial
wall, could be at least partly instrumental in the appearance and persis-
tence of VC [7]. Decreased osteoclast-like activity in conjunction with
increased osteoblast-like activity [51] could therefore be linked to the
calciﬁcation process in vessel walls during CKD. Pi could accelerate
this phenomenon by inhibiting RANKL-induced osteoclastic differentia-
tion of monocytes–macrophages and the bone-resorbing activity of
osteoclastic cells. In addition, phosphate could play a key role in bone
remodelling in CKD patients, who display renal osteodystrophy and es-
pecially in diseases with low bone turnover. Effectively, the CKD pa-
tients could be clustered in two groups relatively to low turnover:
they could be affected by either osteomalacia (low turnover, abnormal
mineralization) or adynamic bone disease (low turnover, normal min-
eralization) [7]. However, evaluating the relative and respective role of
Pi/parathyroid hormone/vitamin D is a real challenging issue in renal
osteodystrophy and CKD-MBD as the other contributors to bone turn-
over could override the inﬂuence of Pi [52]. miR-223 may modulate
the balance between osteoblast-like and osteoclast-like cell activities
(Fig. 6). From this point of view, it is noteworthy that miR-223 has
also been shown to regulate osteoblast-like activities and is increased
in calciﬁed smooth muscle cells in the aorta [19,20]. An imbalance be-
tween mineralization and resorption in the calciﬁed vessel is thus con-
ceivable, and targeting this process could be a useful approach to design
new strategies to trigger the appearance of osteoclast-like cells in calci-
ﬁed vessels in order to prevent or reverse VC. Note however that high
levels of miR-223 were able to obliterate the inhibitory effects of Pi on
the ﬁrst stages of osteoclastogenesis, i.e. osteoclast number and TRAP
activity, butwere not able to affect the later stages of osteoclastogenesis,
such as bone resorption. This suggests that targeting miR-223 is poten-
tially useful, since it will increase osteoclast number and differentiation
(as evidenced by TRAP activity) but not sufﬁcient, and that furtherwork
will be necessary to deﬁne other molecules that will be able to act syn-
ergistically with miR-223 to favour the appearance of functional
osteoclast-like cells in calciﬁed aorta. A comparable approach could
also prove beneﬁcial in bone disorders where modulation of osteoclas-
togenesis would be needed.
Genetic studies using inbred mice have suggested that a combina-
tion of several genes is involved in aortic calciﬁcation [53]. It is therefore
tempting to suggest that, since miRNAs are master gene regulators able
Fig. 6. Inorganic phosphate inhibits osteoclastogenesis by modulating miR-223. Potential roles of miR-223 on bone and calciﬁed vessel during the course of CKD-MBD. miR-223 could be
involved in modulation of the balance between Pi-induced osteoblast-like and osteoclast-like cell activities. The uremic toxin Pi inhibits RANKL-induced osteoclastic differentiation of
monocytes–macrophages and the bone-resorbing activity of osteoclastic cells, promoting VC and osteoporosis. A decreased capacity of monocytes/macrophages to differentiate into
“osteoclast-like cells”would in turn give rise to mineralization by osteoblast-like cells in the arterial wall. miR-223 may modulate the balance between osteoblast-like and osteoclast-like cell
activities, helping to alleviate the imbalance between mineralization and resorption in the calciﬁed vessel.
2211E. M'Baya-Moutoula et al. / Biochimica et Biophysica Acta 1852 (2015) 2202–2212to target more than 100 mRNA targets at a time [54], gene therapy
designed to induce modulation of miR-223 expression could be useful
in VC and/or bone disorders.
5. Conclusions
Taken together, our results have led to novel suggestions concerning
miR-223 regulation during the course of osteoclastogenesis. These
ﬁndings may be useful in understanding the molecular mechanisms
underlying the vascular complications and bone disorders in CKD-
MBD patients, and, in the longer term, in designing innovative miR-223-
targeted treatments.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.08.003.
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